450
Participants
Start Date
August 16, 2024
Primary Completion Date
January 17, 2026
Study Completion Date
February 21, 2026
Placebo
Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
CT-388
CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Neurobehavioral Research, Inc. (NBR), Cedarhurst
National Clinical Research - Richmond, Inc, Richmond
Lucas Research, Inc, Morehead City
Tribe Clinical Research, Greenville
Progressive Medical Research, Port Orange
Tampa Bay Medical Research, Inc., Clearwater
Central Alabama Research, Homewood
Alabama Clinical Therapeutics, LLC, Birmingham
Clinical Research Associates, Inc., Nashville
Alliance for Multispecialty Research, LLC, Knoxville
Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville
Velocity Clinical Research - Cincinnati, Cincinnati
Mercury Street Medical Group, Butte
The Center for Pharmaceutical Research, Kansas City
Velocity Clinical Research - Dallas, Dallas
FutureSearch Trials of Dallas, LLC, Dallas
University of Texas Southwestern, Dallas
Impact Research Institute, Waco
Apex Mobile Clinical Research, Bellaire
Elevate Clinical, Seabrook
Pinnacle Clinical Research, San Antonio
Texas Diabetes & Endocrinology, P.A., Austin
Chrysalis Clinical Research, St. George
The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Mesa
Velocity Clinical Research - Los Angeles, Los Angeles
Ark Clinical Research - Long Beach, Long Beach
Amicis Research Center - West Hills, West Hills
Amicis Research Center, Northridge
Prospective Research Innovations Inc., Rancho Cucamonga
Ark Clinical-Fountain Valley, Fountain Valley
Orange County Research Center, Tustin
Amicis Research Center - Anaheim, Anaheim
Infinity Clinical Research, Norco
Velocity Clinical Research, Providence, East Greenwich
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Carmot Therapeutics, Inc.
INDUSTRY